Bayer, Onyx seek liver-cancer approval for Nexavar

27 June 2007 @ 07:02 am EDT

Bayer AG and Onyx Pharmaceuticals Inc. said on Wednesday that it asked U.S. regulators to approve their Nexavar drug as a treatment for liver cancer.

Nexavar, which is already approved for kidney cancer, earlier this month showed in a study that it could extend the life of patients with advanced liver cancer, adding about three months of survival compared with a placebo.

(Reporting by Lewis Krauskopf)

Copyright 2009 Thomson Reuters. All rights reserved.

E-Newsletters

We value your privacy. Your email address will not be shared.

Home
World
US
Economy
Companies
Tech
Science
Global Markets
Education
Real Estate
Forex
Commodities
Gold & Silver Matters
More Sections
Fashion
Auto
Travel
Health
Law
Entertainment
Sports
Luxury
Art
Books
Tech & Trend
Tools & Features
Topics
Blogs
Market Data
Stock Watch List
Investment Calculator
Financial Glossary
Broker Center
World Business Headlines
Updates
RSS Feeds
IBTimes on Twitter
IBTimes on Facebook
E-Newsletters
Services
Forex Newsfeed
Research
Press Release
About IBTimes
News Licensing
Media Kit
Advertise with Us
About IBTimes
Contact Us
Terms of Service
Privacy Policy